The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | MRD evaluation: a key component of MM management?
Mohamad Mohty, MD, PhD, University Pierre & Marie Curie, Paris, France, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, and Joaquin Martinez-Lopez, MD, PhD, Complutense University of Madrid, Madrid, Spain, discuss if measurable residual disease (MRD) could be used as an endpoint for multiple myeloma (MM), which techniques should be used to measure MRD and how to combine it with imaging techniques. The speakers debate whether MRD status should guide drug development and approval, and highlight that it is important to standardize measurement methods and definitions as much as possible, before using MRD routinely. This roundtable was held at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
